Experiment Index

This section contains proposed experiments to advance our understanding of neurodegenerative diseases and identify potential therapeutic targets. Each experiment proposal is evaluated using a standardized 10-dimension scoring rubric.

Scoring Methodology

For detailed scoring criteria, rubrics, and interpretation guides, see the [Experiment Scoring Methodology](/experiments/scoring-methodology) page.

The scoring system uses 10 dimensions (0-10 scale each) with weights, producing a maximum composite score of 140 points.

Ranked Experiments

This section contains proposed experiments to advance our understanding of neurodegenerative diseases and identify potential therapeutic targets. Each experiment proposal is evaluated using a standardized 10-dimension scoring rubric.

Scoring Methodology

For detailed scoring criteria, rubrics, and interpretation guides, see the [Experiment Scoring Methodology](/experiments/scoring-methodology) page.

The scoring system uses 10 dimensions (0-10 scale each) with weights, producing a maximum composite score of 140 points.

Ranked Experiments

| Rank | Experiment | Score |
|------|------------|-------|
| 1 | [Microglial TREM2 Agonist In Vivo Efficacy](/experiments/trem2-agonist-efficacy) | 131/140 |
| 2 | [Alpha-Synuclein Seed Amplification Assay Validation](/experiments/alpha-synuclein-saas) | 131/140 |
| 3 | [GLP-1 Agonist Neuroprotection Mechanism in Parkinson's Disease](/experiments/glp1-agonist-pd-mechanism) | 125/140 |
| 4 | [Blood-Based Biomarker Panel for Early Alzheimer's Disease Detection](/experiments/blood-biomarker-ad-detection) | 125/140 |
| 5 | [Anti-Tau Immunotherapy Dosing Optimization](/experiments/anti-tau-immunotherapy-dosing) | 121/140 |
| 6 | [NAD+ Augmentation Therapy in Early AD](/experiments/nad-augmentation-therapy-early-ad) | 121.5/140 |
| 7 | [Experiment Proposal: Anti-Aβ + Anti-Tau Combination Therapy in Early AD](/experiments/ad-combination-therapy-trial) | 54/140 |
| 7 | [Multiscale Computational Modeling of Protein Aggregation Kinetics](/experiments/multiscale-protein-aggregation-modeling) | 83/140 |
| 8 | [Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation](/experiments/alpha-synuclein-membrane-nucleation) | 87/140 |
| 2 | [Validation: Membrane-Nucleation in iPSC Neurons](/experiments/membrane-nucleation-ipsc-validation) | 131.5/140 |
| 9 | [Animal Model Comparison for Neurodegenerative Disease Therapeutics](/experiments/animal-model-comparison-neurodegeneration) | 85/140 |
| 1 | [AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy](/experiments/lrrk2-aav-gene-therapy-comparison) | 128/140 |
| 1 | [Autophagy Enhancement Drug Screening for Neurodegeneration](/experiments/autophagy-enhancement-drug-screening) | 140/140 |
| 10 | [Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's Disease](/experiments/astrocyte-ferritin-iron-metabolism-pd) | 114.8/140 |

Last updated: 2026-03-31 06:15 PT

All Proposed Experiments

[Microglial TREM2 Agonist In Vivo Efficacy](/experiments/trem2-agonist-efficacy)

Score: 131/140 | SV:10 F:8 N:9 DI:10 R:7 CE:7 TE:8 EB:9 AU:10 TP:10

[Alpha-Synuclein Seed Amplification Assay Validation](/experiments/alpha-synuclein-saas)

Score: 131/140 | SV:9 F:9 N:8 DI:10 R:8 CE:9 TE:9 EB:8 AU:9 TP:10

[GLP-1 Agonist Neuroprotection Mechanism in Parkinson's Disease](/experiments/glp1-agonist-pd-mechanism)

Score: 125/140 | SV:9 F:8 N:8 DI:9 R:8 CE:7 TE:8 EB:9 AU:10 TP:9

[Blood-Based Biomarker Panel for Early Alzheimer's Disease Detection](/experiments/blood-biomarker-ad-detection)

Score: 125/140 | SV:9 F:8 N:7 DI:10 R:10 CE:8 TE:7 EB:8 AU:8 TP:10

[Anti-Tau Immunotherapy Dosing Optimization](/experiments/anti-tau-immunotherapy-dosing)

Score: 121/140 | SV:9 F:8 N:7 DI:9 R:8 CE:7 TE:8 EB:8 AU:9 TP:9

[NAD+ Augmentation Therapy in Early AD](/experiments/nad-augmentation-therapy-early-ad)

Score: 121.5/140 | SV:9 F:8 N:9 DI:9 R:6 CE:8 TE:8 EB:8 AU:8 TP:9

[Experiment Proposal: Anti-Aβ + Anti-Tau Combination Therapy in Early AD](/experiments/ad-combination-therapy-trial)

Score: 54/140 | SV:9 F:7 N:10 DI:- R:- CE:6 TE:5 EB:- AU:- TP:-

[Multiscale Computational Modeling of Protein Aggregation Kinetics](/experiments/multiscale-protein-aggregation-modeling)

Score: 83/140 | SV:9 F:8 N:10 DI:9 R:8 CE:8 TE:7 EB:7 AU:9 TP:8

[Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation](/experiments/alpha-synuclein-membrane-nucleation)

Score: 87/140 | SV:10 F:8 N:10 DI:10 R:8 CE:8 TE:7 EB:9 AU:10 TP:9

[Validation: Membrane-Nucleation in iPSC Neurons](/experiments/membrane-nucleation-ipsc-validation)

Score: 131.5/140 | SV:9 F:8 N:9 DI:10 R:8 CE:9 TE:7 EB:9 AU:10 TP:10

[Animal Model Comparison for Neurodegenerative Disease Therapeutics](/experiments/animal-model-comparison-neurodegeneration)

Score: 85/140 | SV:10 F:8 N:9 DI:9 R:7 CE:8 TE:7 EB:7 AU:8 TP:10

[AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy](/experiments/lrrk2-aav-gene-therapy-comparison)

Score: 128/140 | SV:10 F:7 N:9 DI:10 R:8 CE:6 TE:7 EB:8 AU:10 TP:10

[Autophagy Enhancement Drug Screening for Neurodegeneration](/experiments/autophagy-enhancement-drug-screening)

Score: 140/140 | SV:10 F:7 N:10 DI:10 R:9 CE:7 TE:6 EB:8 AU:10 TP:10

[Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson's Disease](/experiments/astrocyte-ferritin-iron-metabolism-pd)

Score: 114.8/140 | SV:9 F:7 N:9 DI:10 R:7 CE:7 TE:7 EB:8 AU:9 TP:9

[4R-Tau Targeting Therapies for PSP and CBS](/experiments/4r-tau-targeting-psp-cbs)

Score: 118/140 | SV:10 F:7 N:10 DI:10 R:8 CE:6 TE:6 EB:8 AU:9 TP:9

[Brainstem Circuit Modulation for PSP](/experiments/brainstem-circuit-modulation-psp)

Score: 110/140 | SV:9 F:6 N:9 DI:10 R:8 CE:5 TE:5 EB:7 AU:8 TP:10

[PSP and CBS Biomarker Validation Study](/experiments/psp-cbs-biomarker-validation)

Score: 125/140 | SV:10 F:8 N:9 DI:10 R:9 CE:7 TE:7 EB:8 AU:10 TP:10

Scoring Dimensions

| Dimension | Weight |
|-----------|--------|
| Scientific Value (SV) | 2x |
| Feasibility (F) | 1.5x |
| Novelty (N) | 1.5x |
| Disease Impact (DI) | 2x |
| Reach (R) | 1x |
| Cost Efficiency (CE) | 1x |
| Time Efficiency (TE) | 1x |
| Evidence Base (EB) | 1x |
| Addresses Uncertainty (AU) | 1.5x |
| Translation Potential (TP) | 2x |

Max Score: 140 (10 × 14 = 140)

Related Sections

• [Experiment Scoring Methodology](/experiments/scoring-methodology) — Detailed scoring rubrics and interpretation
• [Therapeutic Targets](/therapeutics/) — Drug candidates and molecular targets
• [Mechanisms](/mechanisms/) — Disease pathways and biological processes
• [Genes](/genes/) — Genetic factors in neurodegeneration
• [Proteins](/proteins/) — Protein players in disease processes
• [Clinical Trials](/clinical-trials/) — Ongoing and completed trials

Overview

This page provides information about Experiment Index.

Coverage Gaps

Missing Experiment Categories

The current Experiment Index focuses heavily on [Alzheimer's](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). The following disease areas lack proposed experiments:

• PSP/CBS experiments — No experiments for 4R-tauopathy, corticobasal degeneration
• MSA experiments — 7 experiments now proposed (ranks 82-88)
• FTD experiments — Limited experiment proposals for frontotemporal dementia subtypes
• Huntington's disease experiments — Missing experiment proposals for CAG repeat therapies

Missing Mechanistic Experiments

The following important mechanistic areas lack dedicated experiment proposals:

• [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology experiments — ALS/FTD-specific experimental designs
• Neuroinflammation profiling — Systems immunology approaches
• Vascular dysfunction experiments — [BBB](/entities/blood-brain-barrier) integrity, cerebral amyloid angiopathy
• Metabolism-neurodegeneration — Metabolic coupling experiments
• Aging models — Geroscience intervention experiments

Action Items

References

This page contains curated content with references to primary scientific literature.

See Also

• [NeuroWiki Home](/home)
• [Index Pages](/all-pages)